Publications by authors named "Lynn Kirkpatrick"

Claim this Profile
C
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
D Lynn Kirkpatrick, Cari Evans, Linda A Pestano, Jeffrey Millard, Matthew Johnston

Clin Transl Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease.
Garth Powis, Emmanuelle J Meuillet, Martin Indarte, Garrett Booher, Lynn Kirkpatrick

Biomed Pharmacother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.
Hei-Cheul Jeung, Roisin Puentes, Alexander Aleshin, Martin Indarte, Ricardo G Correa, Lynn Kirkpatrick

Exp Cell Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Martin Indarte, Roisin Puentes, Marco Maruggi, Nathan T Ihle, Geoffrey Grandjean, Lynn Kirkpatrick

Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
Md Tanvir Hasan, Elizabeth Campbell, Olga Sizova, Veronica Lyle, Giridhar Akkaraju, D Lynn Kirkpatrick

Cancers (Basel)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Martin Indarte, Roisin Puentes, Marco Maruggi, Nathan T Ihle, Geoffrey Grandjean, Lynn Kirkpatrick

Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.
D Lynn Kirkpatrick, William K Schmidt, Ricardo Morales, John Cremin, Julie Seroogy

J Opioid Manag· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.
D Lynn Kirkpatrick, Garth Powis

Antioxid Redox Signal· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incubators for innovators.
Lynn Kirkpatrick

Nat Biotechnol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramesh K Ramanathan, Joe J Stephenson, Glen J Weiss, Linda A Pestano, Ann Lowe, Lynn Kirkpatrick

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?
D Lynn Kirkpatrick, Michelle Weiss, Anton Naumov, Geoffrey Bartholomeusz, R Bruce Weisman

Materials (Basel)· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose M Guillen

Cancer Chemother Pharmacol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
Jörg J Jacoby, Baruch Erez, Maria V Korshunova, Ryan R Williams, Kazuhisa Furutani, Lynn Kirkpatrick

J Thorac Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Dimpy Koul, Ruijun Shen, Yong-Wan Kim, Yasuko Kondo, Yiling Lu, D Lynn Kirkpatrick

Neuro Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of commercial rigid polyurethane foams used as bone analogs for implant testing.
Kayla L Calvert, Kevin P Trumble, Thomas J Webster, Lynn A Kirkpatrick

J Mater Sci Mater Med· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.
Emmanuelle J Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, D Lynn Kirkpatrick

Mol Cancer Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Nathan T Ihle, Robert Lemos, Peter Wipf, Adly Yacoub, Clint Mitchell, D Lynn Kirkpatrick

Cancer Res· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Nathan T Ihle, Robert Lemos, David Schwartz, Junghwan Oh, Robert J Halter, Lynn Kirkpatrick

Mol Cancer Ther· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Mei Y Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan R Williams, D Lynn Kirkpatrick

Mol Cancer Ther· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thioredoxin signaling as a target for cancer therapy.
Garth Powis, D Lynn Kirkpatrick

Curr Opin Pharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
Ramesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, David Friedland, Sylvan B Green

Clin Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Ryan Williams, Amanda F Baker, Nathan T Ihle, Ashley R Winkler, Lynn Kirkpatrick

Cancer Chemother Pharmacol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.
Garth Powis, Nathan Ihle, D Lynn Kirkpatrick

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Garth Powis, Peter Wipf, Stephen M Lynch, Anne Birmingham, D Lynn Kirkpatrick

Mol Cancer Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Amanda F Baker, Tomislav Dragovich, Wendy R Tate, Ramesh K Ramanathan, Denise Roe, D Lynn Kirkpatrick

J Lab Clin Med· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis